Skip to main content

Table 2 Clinical features of TP53 mutant versus TP53/USP8 wild type and USP8 mutant groups

From: TP53 mutations in functional corticotroph tumors are linked to invasion and worse clinical outcome

Variable TP53
mutant
TP53/USP8 wild type P-value USP8 mutant P-valuea  
Age at diagnosis (years), mean ± SD 53  ± 18 43  ± 15 0.069 37  ± 13 0.024 b
Sex (female), n (%) 6/9 (67%) 31/52 (73%) 1.000 25/25 (100%)  ≥ 0.001 c,d
BMI (kg/m2), mean ± SD 30.6  ± 6.0 28.4  ± 5.6 0.312 29.0  ± 7.8 0.641  
Disease presentation, n (%)      0.065    0.060  
 CD 5/9 (56%) 44/52 (85%)   17/25 (68%)   
 CTP-BADX/NS 4/9 (44%) 8/52 (15%)   8/25 (32%)   
Number of prior pituitary surgeries, n (%)      0.009    0.034 c
 0 2/9 (22%) 31/46 (67%)   17/25 (68%)   
 1 4/9 (44%) 13/46 (28%)   6/25 (24%)   
 ≥ 2 3/9 (33%) 2/46 (4%)   2/25 (8%)   
Total number of pituitary surgeries, n (%)      0.018    0.109  
 1 2/9 (22%) 29/48 (60%)   15/25 (60%)   
 2 3/9 (33%) 14/48 (29%)   6/25 (24%)   
 ≥ 3 4/9 (44%) 5/48 (10%)   4/25 (16%)   
Complete tumor resection, n (%) 1/8 (13%) 17/28 (61%) 0.041 14/17 (82%) 0.003 b
Postoperative remission, n (%) 4/9 (44%) 28/46 (61%) 0.467 14/23 (61%) 0.670  
Postoperative tumor control, n (%) 4/8 (50%) 14/26 (54%) 1.000 16/23 (70%) 0.494  
Radiation therapy, n (%) 7/9 (78%) 10/38 (26%) 0.007 7/23 (30%) 0.014 c
Radiation therapy before sample collection, n (%) 3/8 (38%) 2/30 (7%) 0.053 2/15 (13%) 0.074  
Bilateral adrenalectomy, n (%) 4/9 (44%) 9/52 (17%) 0.065 10/25 (40%) 0.048  
Pharmacological treatmentse, n (%) 4/6 (67%) 10/23 (44%) 0.390 4/14 (29%) 0.299  
Preoperative hormone levels          
 Plasma ACTH (pg/ml), median (IQR) 105 (741.0) 96 (253.4) 0.821 100 (944.4) 0.902  
 Serum cortisol (µg/dl), median (range) 29 (19) 23 (2197) 1.000 196 (2469) 0.061  
 24 h-urinary free cortisol (µg/24 h), median (range) 1680 (2860) 433 (10,806) 0.674 447 (2735) 0.809  
 Serum cortisol after low-dose DST (µg/dl), median (IQR) 8.9 (24.2) 20.0 (14.3) 0.638 31.0 (156.9) 0.217  
Postoperative hormone levels
 Plasma ACTH (pg/mL), median (IQR) 106.0 (216.0) 17.8 (89.5) 0.192 20.0 (78.5) 0.341  
 Serum cortisol nadir (µg/dl), median (range) 5.7 (20.8) 7.8 (18.3) 0.907 20.0 (33.3) 0.253  
Disease-specific death, n (%) 3/7 (43%) 1/26 (4%) 0.023 1/25 (4%) 0.010  
  1. a Adjusted P-value for multiple comparisons (TP53 mutant vs. TP53/USP8 wild type vs. USP8 mutant groups)
  2. b P  < 0.05 for TP53 mutant vs. USP8 mutant groups
  3. c P  < 0.05 for TP53 mutant vs. TP53/USP8 wild type groups
  4. d P  < 0.05 for USP8 mutant vs. TP53/USP8 wild type groups
  5. e Pharmacological treatments: pasireotide (n = 6), ketoconazole (n = 5), mitotane (n = 5), temozolamide (n = 4) metyrapone (n = 5), cabergoline (n = 3), bevazizumab (n = 1). Five patients received > 1 pharmacological agent
  6. Bold values indicate P-values < 0.05